Definium Therapeutics

DFTX

Market cap $4.59B

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the pricing of an underwritten public offering of 20,588,236 common shares, without par value, at a public offering price of $34.00 per common share. The gross proceeds to Definium from the offering, before de.

DFTX stock surges 50% as phase III data show its single-dose, investigational MDD therapy delivers rapid, durable symptom improvements and meets all key goals.

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it intends to offer and sell, subject to market conditions, $500 million of its common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. I.

Definium Therapeutics (NASDAQ:DFTX) shares climbed about 53% on Monday after the biopharmaceutical company reported positive topline results from its Phase 3 Emerge study evaluating DT120, an orally disintegrating formulation of lysergide (LSD), in adults with major depressive disorder (MDD). The randomized, double-blind, placebo-controlled trial met its primary endpoint and all key secondary efficacy endpoints.

Definium Therapeutics, Inc. (DFTX) Shareholder/Analyst Call Transcript

Definium Therapeutics skyrocketed Monday after its psychedelics-based depression treatment scored a "best-case" win in final-phase testing.

Definium Therapeutics Inc. (NASDAQ:DFTX) shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with major depressive disorder—with the trial meeting its primary and all key secondary efficacy endpoints.

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase 3 study evaluating a single dose of DT120 (lysergide) ODT 100 µg in adults with major depressive disorder (MDD). Emerge met i.

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast tomorrow at 8 a.m. EDT to discuss topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase 3 study evaluating a single dose of DT120 ODT 100 µg in adults with.

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 155,480 common shares of the Company (the "Options") with effective grant dates of June 15, 2026.